Posts in Case Studies
Identification of ONC201's MOA & Optimization of Analogs and Indications for Imipridone Compound Family

ONC201 was a first-in-class anticancer compounds in Phase II clinical trials, however its binding target and mechanism of action were unknown, which mad future development and therapeutic positioning difficult. Our platform integrated data on ONC201's structure, efficacy, and genomic effects to identify and validate its mechanism of action. Based on the identified binding target, we ranked other imipridone analogs based on predicted selectivity and efficacy, and identified the optimal cancer subtypes for Oncoceutics to pursue clinically. These predictions were validated in vitro, in vivo, and through clinical trials.

Read More